Pharmaceuticals News and Research

RSS

Vending machine to dispense “morning after pills” at college sparks debate

Now students at Shippensburg University in Pennsylvania can get the “morning after” pill by sliding $25 into a vending machine, an idea that has drawn the attention of federal regulators and raised questions about how accessible emergency contraception should be.

7 Feb 2012

ECNP expresses deep concern at withdrawal by AstraZeneca from neuroscience drug research

The European College of Neuropsychopharmacology expresses its deep concern at the recently announced withdrawal by AstraZeneca from neuroscience drug research. AstraZeneca's pull-out is especially disturbing given that it follows a series of similar withdrawals in the last two years by major pharmaceutical companies. There is a growing sense that neuroscience in Europe is now facing a severe crisis.

7 Feb 2012

Preliminary results from Remedy Pharmaceuticals' RP-1127 Phase 2 trial on stroke

Each year, over 700,000 people in the United States suffer a stroke. For most, medical science can do very little. Some will die; a number will suffer debilitating aftereffects. Now, preliminary results of a Phase 2 clinical trial using Remedy Pharmaceuticals' new drug, RP-1127, presented at the 2012 International Stroke Conference in New Orleans on February 2, offer hope to many of these patients.

6 Feb 2012

Mylan acquires two dermatological drugs from Valeant

Mylan Inc. today announced that it has successfully completed the acquisition of two dermatological products from Valeant Pharmaceuticals.

6 Feb 2012

Watson, Acorda partner to introduce tizanidine hydrochloride capsules

Acorda Therapeutics, Inc. today announced that the Company has partnered with Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc. to introduce tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES (tizanidine hydrochloride).

6 Feb 2012

Body's zinc control mechanisms may be key to aggressive breast cancer treatments

The body's control mechanisms for delivering zinc to cells could be key to improving treatment for some types of aggressive breast cancer.

6 Feb 2012

GSK voluntarily pauses enrollment in GSK2251052 clinical trials for cUTI

Anacor Pharmaceuticals announced today that its partner GlaxoSmithKline has voluntarily paused enrollment in its current clinical trials of GSK2251052 due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI).

6 Feb 2012

Valeant divests generic Benzaclin and Efudex to Mylan

Valeant Pharmaceuticals International, Inc. today announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to Mylan Inc..

6 Feb 2012

Soligenix reports positive results from preclinical studies of vaccine thermostabilization technology

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

6 Feb 2012

BioLineRx, Genoscience and RFS Pharma enter agreement for BL-8030 Hepatitis C treatment

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.

6 Feb 2012

EntreMed receives $9.3 million in strategic financing

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received approximately $9.3 million in strategic financing, as previously announced on January 23, 2012.

6 Feb 2012

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults.

6 Feb 2012

Clinuvel submits SCENESSE MAA to EMA for treatment of erythropoietic protoporphyria

Clinuvel Pharmaceuticals Limited today announced that it has submitted a marketing authorisation application (MAA) for its first-in-class drug SCENESSE (afamelanotide 16mg implant) to the European Medicines Agency.

6 Feb 2012

MSL becomes a key link between pharmaceutical industry and stakeholders

Medical Science Liaisons have become a key link between the pharmaceutical industry and key stakeholders such as thought leaders that drive marketplace success. And the role of MSLs will grow even more in the coming years as the pharmaceutical industry relies on them to build relationships across a diverse set of customers.

4 Feb 2012

Al Jazeera speaks with experts about new NTD initiative

Following the announcement on Monday that 13 pharmaceutical companies, several large non-profit organizations, governments, and U.N. agencies are joining forces to fight neglected tropical diseases (NTDs), Al Jazeera's "Inside Story" interviewed several experts in the field, asking, "Why have these diseases been neglected for so long? And how effective will the new plans be to counter these diseases and, in turn, alleviate poverty? Is the target date of 2020 set by the initiative realistic to wipe out some of the world's deadliest conditions? And what is in it for them?" according to the show's summary.

4 Feb 2012

Watson: ANDA for generic Lidoderm remains on track

In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm patent challenge, Watson Pharmaceuticals, Inc. today issued the following statement: Watson's abbreviated new drug application (ANDA) for a generic version of Lidoderm remains on track.

4 Feb 2012

Aggrenox not affected by co-administration of omeprazole: Study

Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the co-administration of omeprazole, a proton pump inhibitor (PPI), frequently used to treat several gastrointestinal conditions. These data were presented at the International Stroke Conference (ISC) in New Orleans.

3 Feb 2012

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

Roche/Genentech/Chugai's pertuzumab plus trastuzumab (Roche/Genentech/Chugai's Herceptin) and docetaxel (Sanofi's Taxotere, generics) will become Decision Resources' proprietary clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015.

3 Feb 2012

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

3 Feb 2012

Dr. Reddy’s third quarter revenues increase 46% to $522 million

Dr. Reddy's Laboratories Ltd. today announced its unaudited consolidated financial results for the quarter ended December 31, 2011 under International Financial Reporting Standards.

3 Feb 2012

Pharmaceuticals News and Research

Vending machine to dispense “morning after pills” at college sparks debate

ECNP expresses deep concern at withdrawal by AstraZeneca from neuroscience drug research

Preliminary results from Remedy Pharmaceuticals' RP-1127 Phase 2 trial on stroke

Mylan acquires two dermatological drugs from Valeant

Watson, Acorda partner to introduce tizanidine hydrochloride capsules

Body's zinc control mechanisms may be key to aggressive breast cancer treatments

GSK voluntarily pauses enrollment in GSK2251052 clinical trials for cUTI

Valeant divests generic Benzaclin and Efudex to Mylan

Soligenix reports positive results from preclinical studies of vaccine thermostabilization technology

BioLineRx, Genoscience and RFS Pharma enter agreement for BL-8030 Hepatitis C treatment

EntreMed receives $9.3 million in strategic financing

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Clinuvel submits SCENESSE MAA to EMA for treatment of erythropoietic protoporphyria

MSL becomes a key link between pharmaceutical industry and stakeholders

Al Jazeera speaks with experts about new NTD initiative

Watson: ANDA for generic Lidoderm remains on track

Aggrenox not affected by co-administration of omeprazole: Study

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Dr. Reddy’s third quarter revenues increase 46% to $522 million

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence